Robert Chang, MD
Nephrology · Corona, CANPI 1992894885
Payments from drug & device makers
Across 117 payments — averaging $38.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Vifor Pharma, Inc.$406
- Otsuka America Pharmaceutical, Inc.$400
- AstraZeneca$307
- Akebia Therapeutics Inc$131
- OPKO Pharmaceuticals, LLC$81
- plus $316 from 7 others
What the payments were for
- Speaking & faculty fees$2,36053%
- Food & beverage$2,03145%
- Education$992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 39 | $2,848 |
| Vifor Pharma, Inc. | 19 | $406 |
| Otsuka America Pharmaceutical, Inc. | 20 | $400 |
| AstraZeneca | 14 | $307 |
| Akebia Therapeutics Inc | 7 | $131 |
| OPKO Pharmaceuticals, LLC | 4 | $81 |
| Mallinckrodt Hospital Products Inc. | 3 | $80 |
| Mallinckrodt Enterprises LLC | 3 | $79 |
| Fresenius USA Marketing, Inc. | 3 | $46 |
| Medtronic | 1 | $46 |
| Bayer | 2 | $37 |
| Dexcom, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,490 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $45,451 |
| Sevelamer Carbonate | 134 | $31,284 |
| Lanthanum Carbonate | 20 | $11,708 |
| Sodium Polystyrene Sulfonate | 83 | $6,412 |
| Calcium Acetate | 29 | $4,052 |
| Furosemide | 102 | $1,664 |
| Hydralazine Hcl | 60 | $1,488 |
| Atorvastatin Calcium | 109 | $1,375 |
| Gentamicin Sulfate | 37 | $1,226 |
| Calcitriol | 61 | $1,202 |
| Amlodipine Besylate | 96 | $1,165 |
| Losartan Potassium | 94 | $1,137 |
| Nifedipine ErNifedipine | 26 | $1,122 |
| Cinacalcet Hcl | 29 | $923 |
| Lisinopril | 65 | $848 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Corona
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.